2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective D1 dopamine receptor agonist used primarily as a research tool.
| Descriptor ID |
D015647
|
| MeSH Number(s) |
D03.633.100.079.800
|
| Concept/Terms |
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
- 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-
SK&F-38393- SK&F-38393
- SK&F 38393
- SK&F38393
- SKF38393
- SKF-38393
- SKF 38393
- R-SK&F 38393
- RSK&F 38393
- SKF 38393-A
- SKF 38393 A
- SKF 38393A
|
Below are MeSH descriptors whose meaning is more general than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
Below are MeSH descriptors whose meaning is more specific than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
This graph shows the total number of publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in this website by year, and whether "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in Profiles.
-
Injection of D1 receptor antagonist SCH23390 into the periaqueductal gray attenuates morphine withdrawal symptoms in rats. Neurosci Lett. 2020 01 01; 714:134502.
-
Kidney dopamine D1-like receptors and angiotensin 1-7 interaction inhibits renal Na+ transporters. Am J Physiol Renal Physiol. 2019 10 01; 317(4):F949-F956.
-
Rhodium-catalyzed asymmetric addition of arylboronic acids to ?-nitroolefins: formal synthesis of (S)-SKF 38393. Org Lett. 2013 Nov 15; 15(22):5730-3.
-
Transcription factor Nrf2 protects renal dopamine D1 receptor function during oxidative stress. Hypertension. 2013 Sep; 62(3):512-7.
-
Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats. Hypertension. 2012 May; 59(5):1029-36.
-
Novel role of NF-?B-p65 in antioxidant homeostasis in human kidney-2 cells. Am J Physiol Renal Physiol. 2012 Jun 01; 302(11):F1440-6.
-
Oxidative stress alters renal D1 and AT1 receptor functions and increases blood pressure in old rats. Am J Physiol Renal Physiol. 2011 Jan; 300(1):F133-8.
-
Exercise reduces oxidative stress but does not alleviate hyperinsulinemia or renal dopamine D1 receptor dysfunction in obese rats. Am J Physiol Renal Physiol. 2011 Jan; 300(1):F98-104.
-
Exercise activates redox-sensitive transcription factors and restores renal D1 receptor function in old rats. Am J Physiol Renal Physiol. 2009 Nov; 297(5):F1174-80.
-
Renal proximal tubules from old Fischer 344 rats grow into epithelial cells in cultures and exhibit increased oxidative stress and reduced D1 receptor function. Am J Physiol Cell Physiol. 2008 Nov; 295(5):C1326-31.